Where can I find news about 9926.HK?

The latest press releases, SEC filings, and earnings call transcripts for Akeso, Inc. (9926.HK) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.

Where are 9926.HK's SEC filings?

Akeso, Inc. (9926.HK)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

When was 9926.HK's last earnings call?

The most recent earnings call transcript for Akeso, Inc. (9926.HK) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

9926.HK

Akeso, Inc.

HKSE·Biotechnology · Healthcare

HK$104.70HK$5.80+5.86%

Market capHK$96.32B·Market closed·Jul 23 5:53 AM UTC

Press Releases

Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC
/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study
prnewswire.comJul 20, 2026 · 1:32 AM
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody,
prnewswire.comMay 31, 2026 · 9:00 AM
Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled
prnewswire.comMay 15, 2026 · 3:43 AM
Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating
prnewswire.comApr 20, 2026 · 10:54 PM
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
/PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The
prnewswire.comJan 28, 2026 · 11:51 PM
Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
/PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal
prnewswire.comJan 13, 2026 · 10:54 PM
Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
/PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its
prnewswire.comJan 6, 2026 · 9:50 PM
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase
prnewswire.comDec 11, 2025 · 9:31 PM

SEC Filings

No recent filings indexed.

Transcripts

PRO

Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.

Click below to see what's inside, then upgrade to read every transcript for 9926.HK and 80,000+ other tickers.

Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.

Frequently Asked Questions About 9926.HK

Where can I find news about 9926.HK?: The latest press releases, SEC filings, and earnings call transcripts for Akeso, Inc. (9926.HK) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.
Where are 9926.HK's SEC filings?: Akeso, Inc. (9926.HK)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
When was 9926.HK's last earnings call?: The most recent earnings call transcript for Akeso, Inc. (9926.HK) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

Akeso, Inc.

Frequently Asked Questions About 9926.HK

Akeso, Inc.

Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026

Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026

Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

Frequently Asked Questions About 9926.HK

Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026

Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026

Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab